-
Biorestorative Therapies, Inc. (BRTX) Confirms No Material Impact from Reciprocal Tariffs
-
BioRestorative (BRTX) Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
-
BioRestorative Therapies, Inc. (BRTX) Tops Q3 EPS by 31c
-
BioRestorative Therapies Inc. (BRTX) PT Raised to $18 at Roth/MKM
-
BioRestorative Therapies, Inc. (BRTX) Tops Q2 EPS by 5c
-
Roth/MKM Reiterates Buy Rating on BioRestorative Therapies Inc. (BRTX)
-
Roth/MKM Reiterates Buy Rating on BioRestorative Therapies Inc. (BRTX)

